-
Mashup Score: 0AI Tech Firm SandboxAQ Adds $300M to Ramp Up Development of LQMs for Drug Discovery & More - MedCity News - 5 day(s) ago
Applications of SandboxAQ’s large quantitative models (LQMs) technology include running simulations that identify new biomarkers and optimize clinical development of drug candidates. The company spun out of Alphabet in 2022.
Source: medcitynews.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 3Online Event - 1 month(s) ago
Biopharma companies face unique challenges in scaling AI-and those challenges vary greatly depending on whether you’re at a small or large biopharma. While large biopharma is pushing ahead with nearly 3x the rate of AI adoption of smaller companies (73% vs. 26%), gaps in AI readiness are evident across both segments, according to the upcoming State of Tech in Biopharma report. Just 14% of large biopharma and 3% of small biopharma report being fully prepared for AI across the critical dimensions of
Source: www.workcast.comCategories: General Medicine News, Future of MedicineTweet-
LAST CHANCE! TODAY, experts from AbbVie and Benchling will share insights into the current tech landscape, AI readiness, and the strategies for digital transformation shaping large and small biopharma. REGISTER: https://t.co/0k3RMM70pd @benchling #AI #DrugDiscovery https://t.co/opKZD8kUB9
-
-
Mashup Score: 6Online Event - 1 month(s) ago
Biopharma companies face unique challenges in scaling AI-and those challenges vary greatly depending on whether you’re at a small or large biopharma. While large biopharma is pushing ahead with nearly 3x the rate of AI adoption of smaller companies (73% vs. 26%), gaps in AI readiness are evident across both segments, according to the upcoming State of Tech in Biopharma report. Just 14% of large biopharma and 3% of small biopharma report being fully prepared for AI across the critical dimensions of
Source: www.workcast.comCategories: General Medicine News, Future of MedicineTweet-
DON'T MISS OUT! On 12/4, experts from AbbVie and Benchling will share insights into the current tech landscape, AI readiness, and the strategies for digital transformation shaping large and small biopharma. REGISTER: https://t.co/mUB2UUl6Uz @benchling #AI #DrugDiscovery https://t.co/xCRhud7CnK
-
-
Mashup Score: 15Online Event - 2 month(s) ago
Biopharma companies face unique challenges in scaling AI-and those challenges vary greatly depending on whether you’re at a small or large biopharma. While large biopharma is pushing ahead with nearly 3x the rate of AI adoption of smaller companies (73% vs. 26%), gaps in AI readiness are evident across both segments, according to the upcoming State of Tech in Biopharma report. Just 14% of large biopharma and 3% of small biopharma report being fully prepared for AI across the critical dimensions of
Source: www.workcast.comCategories: General Medicine News, Future of MedicineTweet-
NEW WEBINAR! On 12/4, experts from AbbVie and Benchling will share insights into the current tech landscape, AI readiness, and the strategies for digital transformation shaping large and small biopharma. REGISTER: https://t.co/z3mE5ZaxrT @benchling #AI #DrugDiscovery https://t.co/2iY1wwd0uo
-
-
Mashup Score: 0AI-Designed Insilico Drug Flashes Signs of Efficacy in Lung Disease, But Rivals Are Still Ahead - MedCity News - 3 month(s) ago
Insilico Medicine’s idiopathic pulmonary fibrosis drug led to dose-dependent improvement in lung function in a mid-stage study. Meanwhile, Pliant Therapeutics and PureTech Health are also making Phase 2 progress while Boehringer Ingelheim is planning a regulatory submission supported by its IPF drug’s Phase 3 data.
Source: medcitynews.comCategories: General Medicine News, General HCPsTweet-
#AI-Designed Insilico Drug Flashes Signs of Efficacy in Lung Disease, But Rivals Are Still Ahead | #drugdiscovery https://t.co/uJsbSmDO7o
-
-
Mashup Score: 0Google DeepMind unveils AlphaProteo for AI drug design - 4 month(s) ago
AlphaProteo was created to advance drug design and disease understanding by helping researchers configure high-strength proteins that bind to molecules.
Source: www.mobihealthnews.comCategories: General Medicine News, General HCPsTweet-
.@GoogleDeepMind unveils AlphaProteo for #AI drug design- AlphaProteo was created to advance drug design and disease understanding by helping researchers configure high-strength proteins that bind to molecules | #drugdiscovery https://t.co/Wmnikmpn2c
-
-
Mashup Score: 0AI-enabled drug discovery company Xaira launches with $1B - 9 month(s) ago
Xaira’s CEO, Dr. Marc Tessier-Lavigne, resigned as president of Stanford University last August due to controversy over inaccuracies discovered in his lab’s scientific papers.
Source: www.mobihealthnews.comCategories: General Medicine News, Future of MedicineTweet-
#AI-enabled #drugdiscovery company Xaira launches with $1B https://t.co/AohDY6sq6x
-
-
Mashup Score: 7
Recursion CEO Chris Gibson, PhD, predicts AI will cut drug discovery costs and discusses his company’s collaboration with Nvidia.
Source: www.genengnews.comCategories: General Medicine News, Future of MedicineTweet-
Drugs, Dollars, and Data: Recursion Eyes Cost Savings from AI Drug Discovery @RecursionPharma CEO @RecursionChris predicts #AI will cut #drugdiscovery costs and discusses his company's collaboration with @Nvidia. Learn more: https://t.co/UIZTBS8lOb https://t.co/yZ3kCyMZBl
-
-
Mashup Score: 7
Recursion CEO Chris Gibson, PhD, predicts AI will cut drug discovery costs and discusses his company’s collaboration with Nvidia.
Source: www.genengnews.comCategories: General Medicine News, Future of MedicineTweet-
Drugs, Dollars, and Data: Recursion Eyes Cost Savings from AI Drug Discovery @RecursionPharma CEO @RecursionChris predicts #AI will cut #drugdiscovery costs and discusses his company's collaboration with @Nvidia. Learn more: https://t.co/UIZTBS8lOb https://t.co/yZ3kCyMZBl
-
-
Mashup Score: 7
Recursion CEO Chris Gibson, PhD, predicts AI will cut drug discovery costs and discusses his company’s collaboration with Nvidia.
Source: www.genengnews.comCategories: General Medicine News, Future of MedicineTweet-
Drugs, Dollars, and Data: Recursion Eyes Cost Savings from AI Drug Discovery @RecursionPharma CEO @RecursionChris predicts #AI will cut #drugdiscovery costs and discusses his company's collaboration with @Nvidia. Learn more: https://t.co/UIZTBS8lOb https://t.co/yZ3kCyMZBl
-
#AI Tech Firm @SandboxAQ Adds $300M to Ramp Up Development of LQMs for #DrugDiscovery - Applications of SandboxAQ’s large quantitative models (LQMs) tech include running simulations that identify new biomarkers, optimize clinical dvlpmt of drug candidates https://t.co/y7gJEObaCe